T
Timothy D Mastro
Researcher at Durham University
Publications - 30
Citations - 2142
Timothy D Mastro is an academic researcher from Durham University. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Population. The author has an hindex of 12, co-authored 30 publications receiving 1872 citations. Previous affiliations of Timothy D Mastro include FHI 360.
Papers
More filters
Journal ArticleDOI
Preexposure Prophylaxis for HIV Infection among African Women
Lut Van Damme,Amy Corneli,Khatija Ahmed,Johan Lombaard,Saidi Kapiga,Mookho Malahleha,Rachel Manongi,Jacob Onyango,Lucky Temu,Modie Constance Monedi,Mankalimeng Makanda,Lisa Saylor,Haddie Kiernan,Stella Kirkendale,Christina Wong,Robert M. Grant,Angela D. M. Kashuba,Kavita Nanda,Justin Mandala,Katrien Fransen,Jennifer Deese,Tania Crucitti,Timothy D Mastro,Douglas Taylor +23 more
TL;DR: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo, and drug adherence appeared to be low.
Journal ArticleDOI
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Danuta Pieniazek,Mark A. Rayfield,Dale J. Hu,John N. Nkengasong,Stefan Z. Wiktor,Robert W. Downing,Benon Biryahwaho,Timothy D Mastro,Amilcar Tanuri,Vincent Soriano,Renu B. Lal,Timothy J. Dondero +11 more
TL;DR: The high prevalence of PRI-associated substitutions represent natural polymorphisms occurring inPRI-naive patients infected with HIV-1 strains of subtypes A−H and the significance of distinct mutation patterns identified for subtype B and non-B strains warrants further clinical evaluation.
Journal Article
Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults -- seven African countries 2004-2013.
Andrew F. Auld,Simon Agolory,Ray W. Shiraishi,Fred Wabwire-Mangen,Gideon Kwesigabo,Modest Mulenga,Sebastian Hachizovu,Emeka Asadu,Moise Zanga Tuho,Virginie Ettiègne-Traoré,Francisco Mbofana,Velephi Okello,Charles Azih,Julie A. Denison,Sharon Tsui,Olivier Koole,Harrison Kamiru,Harriet Nuwagaba-Biribonwoha,Charity Alfredo,Kebba Jobarteh,Solomon Odafe,Dennis Onotu,Kunomboa A. Ekra,Joseph S. Kouakou,Peter Ehrenkranz,George Bicego,Kwasi Torpey,Ya Diul Mukadi,Eric van Praag,Joris Menten,Timothy D Mastro,Carol Dukes Hamilton,Mahesh Swaminathan,E. Kainne Dokubo,Andrew L. Baughman,Thomas J. Spira,Robert Colebunders,David R. Bangsberg,Richard Marlink,Aaron Zee,Jonathan E. Kaplan,Tedd V. Ellerbrock +41 more
TL;DR: Evidence-based interventions to reduce LTFU for adolescent and young adult ART enrollees could help reduce mortality and HIV incidence in this age group.
Journal Article
Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand.
Dale J. Hu,Shambavi Subbarao,Suphak Vanichseni,Philip A. Mock,Ramos A,Lily Nguyen,Thanyanan Chaowanachan,Griensven Fv,Kachit Choopanya,Timothy D Mastro,Jordan W. Tappero +10 more
TL;DR: Determination of the frequency and incidence of dual HIV-1 subtype infections among recent seroconvertors from a cohort of injection drug users in Bangkok, Thailand demonstrates that HIV- 1 superinfection is not uncommon in a population with high HIV-2 incidence with more than one circulating strain.
Journal ArticleDOI
Development and deployment of COVID-19 vaccines for those most vulnerable.
Wayne C. Koff,Theodore Schenkelberg,Tere Williams,Ralph S. Baric,Adrian B. McDermott,Cheryl M. Cameron,Mark J. Cameron,Matthew B. Friemann,Gabriele Neumann,Yoshihiro Kawaoka,Yoshihiro Kawaoka,Alyson A. Kelvin,Ted M. Ross,Stacey Schultz-Cherry,Timothy D Mastro,Frances Priddy,Kristine A. Moore,Julia T. Ostrowsky,Michael T. Osterholm,Jaap Goudsmit +19 more
TL;DR: In this article, the authors address the challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable in low-resource settings where vaccine access is historically low.